- Home
- APPS vs CHRS Comparison
APPS vs CHRS Comparison
Compare APPS & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APPS | CHRS |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.5M | 296.8M |
| IPO Year | 2012 | 2014 |
Fundamental Metrics
Financial Performance| Metric | APPS | CHRS |
|---|---|---|
| Price | $6.95 | $1.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $6.25 | $5.51 |
| AVG Volume (30 Days) | ★ 2.4M | 1.3M |
| Earning Date | 06-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 62.92 | ★ 472.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $103,569,000.00 | N/A |
| Revenue This Year | $15.60 | $73.08 |
| Revenue Next Year | $11.34 | $30.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 38.55 | N/A |
| 52 Week Low | $2.74 | $0.72 |
| 52 Week High | $8.28 | $2.62 |
Technical Indicators
Market Signals| Indicator | APPS | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 88.06 | 50.35 |
| Support Level | $6.05 | $1.55 |
| Resistance Level | $7.13 | $1.80 |
| Average True Range (ATR) | 0.40 | 0.11 |
| MACD | 0.21 | -0.00 |
| Stochastic Oscillator | 83.31 | 34.88 |
Price Performance
Historical ComparisonAbout APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.